Use of Adjuvant Radiation Therapy for Breast Cancer: A Misunderstanding

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

I would like to comment about Dr. Vicente Valero’s response to Dr. Padmini Iyer’s question regarding adjuvant therapy for a postmenopausal woman with stage IIIA breast cancer. Although Dr. Valero’s response was quite detailed with regard to chemotherapy, no mention was made about the role of radiation therapy in patients with advanced breast cancer.

I would like to comment about Dr. Vicente Valero’s response to Dr. Padmini Iyer’s question regarding adjuvant therapy for a postmenopausal woman with stage IIIA breast cancer. Although Dr. Valero’s response was quite detailed with regard to chemotherapy, no mention was made about the role of radiation therapy in patients with advanced breast cancer.

I am a second-year resident in radiation oncology and recently finished a rotation on our breast cancer service. The patient Dr. Iyer is treating should be considered for postmastectomy radiation therapy both on the basis of her large primary tumor and the number of involved nodes.

Recent Studies

Recent studies by groups in Denmark (Overgaard M et al: N Engl J Med 337:949, 1997) and Canada (Ragaz J et al: N Engl J Med 337:956, 1997) demonstrated not only increased local control with chest wall irradiation in addition to chemotherapy but also improved survival for patients with stage II/III breast cancer.

On the basis of these studies, we are now treating many more patients with postmastectomy radiation therapy. We treat the chest wall and both the axillary and supraclavicular lymph nodes.

Although this patient’s prognosis is poor, I think that radiation therapy should be considered in addition to chemotherapy. In the Danish study, chemotherapy plus radiation therapy improved survival and local control regardless of tumor size, grade, or the number of positive nodes.

In addition, I noticed that no mention was made of the role for hormonal therapy, as this patient was estrogen-receptor/progesterone-receptor positive.

PETER WHITCOPF, MD
Department of Radiation OncologyUniversity of Virginia Health Sciences CenterCharlottesville, Virginia

Dr. Valero Responds:

My answer to the Oncology Rounds question dealt solely with answering the question posed by Dr. Iyer about adjuvant therapy for a 59-year-old patient with stage IIIA breast cancer. Although I was asked to discuss only the role of additional adjuvant chemotherapy, including high-dose chemotherapy, in patients in this situation, certainly I concur with Drs. Whitcopf and Ko about the role of radiation therapy.

It is our standard of care at M.D. Anderson to give chest wall and peripheral lymphatic irradiation, including axillary, supraclavicular, and internal mammary lymph nodes, to these patients at the completion of chemotherapy. It is also our standard of care to give tamoxifen (Nolvadex), 20 mg daily for 5 years, to patients in this situation.

VICENTE VALERO, MD
Associate Internist/Associate Professor of MedicineThe University of Texas M.D. Anderson Cancer CenterHouston, Texas

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content